Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04428736 · ClinicalTrials.gov registry record
Evaluating Cascade Communication Methods
A clinical trial of BRCA1 Mutation and BRCA2 Mutation, sponsored by University of Pennsylvania.
- Active
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT04428736: Active study of BRCA1 Mutation and BRCA2 Mutation, sponsored by University of Pennsylvania.
NCT04428736 is a study of BRCA1 Mutation and BRCA2 Mutation that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 100 participants, below the 570-participant average among 15 other BRCA1 Mutation trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04428736, a study of BRCA1 Mutation and BRCA2 Mutation, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Hereditary cancer programs face challenges with respect to effective communication of genetic test results within families and uptake of genetic testing by relatives. This study aims to determine if a "disclosure toolkit" provided to the index participant (carrier of cancer risk gene mutation) contributes to sharing genetic test results with relatives, if there are preferred disclosure methods, and whether toolkit use contributes towards at-risk relatives pursuing genetic testing.
Primary Outcome
Determine if a "Disclosure Toolkit" contributes to participant sharing of genetic test result with at-risk relatives, and if so, which method is most useful for aiding in communication of results and decisions to undergo genetic counseling and testing.
Conditions Studied
Interventions
- BEHAVIORAL Disclosure Toolkit
Study Locations (1)
Pennsylvania
- Abramson Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-02-19 |
| Est. Completion | 2025-12-31 |
What the registry record for NCT04428736 still lists
NCT04428736 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 570-participant average among 15 other BRCA1 Mutation trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with BRCA1 Mutation appearing as the primary indexed condition, and to 1 intervention - of which Disclosure Toolkit is the first listed.
NCT04428736 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04428736 about?
NCT04428736 is a clinical study titled "Evaluating Cascade Communication Methods". Hereditary cancer programs face challenges with respect to effective communication of genetic test results within families and uptake of genetic testing by relatives. This study aims to determine if a "disclosure toolkit" provided to the index participant (carrier of cancer risk gene mutation) contr...
What is the current status of trial NCT04428736?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2020-02-19. Estimated completion is 2025-12-31.
What conditions does trial NCT04428736 study?
This clinical trial studies the following conditions: BRCA1 Mutation, BRCA2 Mutation.
What interventions are being tested in trial NCT04428736?
The interventions under investigation include: Disclosure Toolkit (BEHAVIORAL).
Who is sponsoring clinical trial NCT04428736?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04428736 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for BRCA1 Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04428736's enrollment target sits among peer trials
100 8th of 15 higher than 8 of 15 other BRCA1 Mutation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other BRCA1 Mutation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results
RECRUITING · NA
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Combination Therapy in Cancers With Mutations in DNA Repair Genes
RECRUITING · Phase 1
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
RECRUITING · Phase 1
-
Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI